Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 23, 2025 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday,...
July 18, 2025 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

THE WOODLANDS, Texas, July 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from a study of patients describing the impact of diabetic peripheral...
June 23, 2025 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a...
June 18, 2025 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

THE WOODLANDS, Texas, June 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from a study evaluating the impact of sotagliflozin on hypoglycemia in...
May 29, 2025 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

THE WOODLANDS, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2025 Jefferies...
May 19, 2025 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

Lexicon is evaluating the safety and efficacy of sotagliflozin in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) Pivotal Phase 3 clinical trial is actively...
May 13, 2025 16:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025...
May 06, 2025 16:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C....
May 06, 2025 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday, May...
April 02, 2025 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual...